Hi ,
|
Please join me tomorrow at 4 pm BST/ 8 am PT for a live Zoom all about the European Bioeconomy with Fiona Mischel from
SynBioBeta, Richard Kitney from SynbiCITE/Imperial College, Natsai Audrey Chieza from Faber Futures, and Orr Yarkoni from Colorifix.
|
 |
Richard Kitney, Natsai Audrey Chieza, and Orr Yarkoni.
In case you missed it at SynBioBeta 2022, Sean McClain and Amy Webb gave us a glimpse into the future of Al-enabling
drug discovery. Absci is developing protein-based drugs, including Bionic Proteins™ with nonstandard amino acids, and other drug designs that may be impossible to make with other technologies.
|
 |
Amy Webb, CEO and Founder of the Future Today Institute, and Sean McClain, CEO and Founder of Absci, at SynBioBeta 2022.
The future of science is distributed. If it's not obvious to you yet, it soon will be. And distributed science will be a big theme at SynBioBeta 2023. We're going to be back in Oakland, May 23-25, 2023. You can get your early bird tickets here. Congratulations to Paul Kohlhaas, CEO of Molecule, for raising $12.7 million in
seed funding. They are democratizing biopharma research and development, and creating an open ecosystem that assists researchers in raising funds for impactful research projects in a community-driven way.
|
 |
Paul Kohlhaas, CEO of Molecule.
Eden Brew, a company making milk in a lab using the same natural fermentation process that happens in dairy cows, has super-sized a capital raising and is now seeking up to $20 million after bedding down a core $5 million raising.
Congratulations to Amai Proteins for winning the 2022 Extreme Tech Challenge Competition! The company is producing designer proteins intended to offer healthy sugar substitutes.
|
Congratulations to Benjamin Oakes (pictured below), CEO and Co-Founder of Scribe Therapeutics, for being named to the MIT Technology Review 35 Innovators Under
35. Scribe Therapeutics is dedicated to shaping the future of Genetic Medicine for patients in need by building safer and more effective CRISPR genetic modification tools.
|
 |
|
And finally, congratulations to Shannon Nangle (pictured below), a Research Scientist working on the Wyss Institute Project "Circe", which focuses on commercializing CO2-based microbial fermentation, for being named to the MIT Technology Review 35 Innovators Under 35.
|
 |
Regards,
John
---
John Cumbers
Founder, SynBioBeta
|
|
|
Featured News
|
|
|
 |
Touchlight signs patent license agreement with Pfizer for the use of dbDNA for the manufacture of mRNA-based vaccines, therapeutics and gene therapies |
Keep Reading
»
|
|
 |
Bacteria for blastoff: Using microbes to make supercharged new rocket fuel |
Scientists have developed a new class of energy-dense biofuels based on one of nature’s most unique molecules
|
Keep Reading »
|
|
|
 |
Download the application note to learn how Inscripta’s OnyxTM Digital Genome Engineering Platform can be used for rapid protein engineering to optimize activity, function, and expression.
|
Keep Reading »
|
|
 |
Advancing synthetic biology with automation |
Without automation, companies developing single products or single solutions will face scale-up problems and be forced to pivot, leaving those who develop platforms or processes with the upper hand to better adapt to the growing automation demands.
|
Keep Reading »
|
|
|
|
|
Who's hiring?
|
- Scientist/ Senior Scientist, Inscripta, Pleasanton, CA
- Senior Software Engineer/ Staff Software Engineer, Inscripta, Pleasanton, CA
- Bioinformatics Software Engineer/ Senior Engineer, Inscripta, Pleasanton, CA or Boulder, CO
- Account Executive - East Coast, Inscripta, East Coast
- Senior Lab Automation Systems Engineer, Inscripta, Pleasanton, CA
- Research Associate, Inscripta, Boulder, CO
- Scientist / Senior Scientist, Stemloop, Evanston, IL
- Engineering Technician, Inscripta, Pleasanton, CA
|
|
|
|
SynBioBeta, LLC
3559 Mount Diablo Boulevard #2, Lafayette, CA 94549
info@synbiobeta.com
If you no longer wish to receive our emails, you can unsubscribe here.
Modify Your Email Preferences
|
|
|
|
|
